Amgen (AMGN) is a Top-Ranked Growth Stock: Should You Buy?

Amgen (AMGN) is highlighted as a potential growth opportunity, despite its Zacks #3 (Hold) rank, due to strong underlying metrics including an 'A' VGM Score and 'B' Growth Style Score. The biotech firm forecasts 5.1% year-over-year earnings growth for the current fiscal year, supported by five recent analyst upgrades for fiscal 2025 estimates, which increased the Zacks Consensus Estimate to $20.85 per share. With a history of exceeding earnings expectations by an average of 8.3% and new growth products offsetting biosimilar competition for older drugs, AMGN merits consideration for growth-focused portfolios.

Analysis

Amgen (AMGN) presents a nuanced investment case, characterized by a neutral Zacks #3 'Hold' rating that contrasts with strong underlying growth and value metrics, including a top-tier 'A' VGM Score. The company is navigating a critical product lifecycle transition where declining sales from legacy drugs like Enbrel, challenged by biosimilar competition, are being offset by its portfolio of growth drivers such as Prolia and Xgeva. This transition is supported by a solid financial outlook, with a forecasted year-over-year earnings growth of 5.1% for the current fiscal year. Reinforcing this positive outlook, five analysts have revised their fiscal 2025 earnings estimates upward over the past 60 days, pushing the consensus estimate to $20.85 per share. Furthermore, Amgen has a consistent history of outperformance, historically beating earnings estimates by an average of 8.3%, suggesting a potential for conservative guidance and operational strength.

Key Decisions for Investors

• Given the combination of a neutral 'Hold' rating with strong 'A' VGM and 'B' Growth scores, investors may consider the stock a candidate for accumulation, particularly on any price weakness.
• Investors should closely monitor revenue trends from Amgen's growth portfolio to ensure it continues to successfully counterbalance the erosion of sales from its legacy drugs facing biosimilar competition.
• The positive analyst revisions for fiscal 2025 and a history of earnings beats suggest upside potential, making it prudent to watch for any change in the Zacks Rank as a potential catalyst for re-evaluation.